Evolving Strategies for the Management of Recurrent C. difficile Infection in Patients with IBD

Monday, December 5, 2022

1:00 PM – 2:00 PM

Location: Northern Hemisphere A

Chair(s)

Jessica R. Allegretti, MD,MPH

Director, Crohn's and Colitis Center; 2020 Sherman Prize Emerging Leader Recipient
Brigham and Women's Hospital
Harvard University
Cambridge, Massachusetts

Speaker(s)

Monika Fischer, MD, MSc.

Professor of Medicine
Indiana University Health
Indianapolis, Indiana
Robert Orenstein, DO

Chair, Infectious Diseases
Mayo Clinic Arizona
Phoenix, Arizona

Disclosure(s):

Robert Orenstein, DO: disclosed no relevant financial relationship with any ineligible company (commercial interest).

This session is supported by an independent educational grant from Seres Therapeutics, Inc. & Aimmune Therapeutics.

1:00 PM Introduction and Pre-Activity Survey
Jessica R. Allegretti, MD MPH

1:05 PM Overview of CDI in Patients with IBD
Monika Fischer, MD, MSc, FACG, AGAF

1:20 PM Initial and Recurrent CDI Treatment Options
Robert Orenstein, DO

1:35 PM Fecal Microbiota Transplantation and Microbiome-Based Therapies
Jessica R. Allegretti, MD, MPH

1:50 PM Cases, Q&A, and Post-Activity Survey
Jessica R. Allegretti, MD, MPH; Monika Fischer, MD, MSc, FACG, AGAF; Robert Orenstein, DO

Learning Objectives:

Describe the epidemiology, burden, and management challenges associated with initial and recurrent CDIs in patients with IBD
Assess the efficacy and safety data associated with current and emerging non-antibiotic therapies for the management and prevention of recurrent CDI
Implement appropriate, evidence-based strategies for the management and prevention of recurrent CDIs in patients with IBD